Search for a trial

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

This study has been transitioned to CTIS with ID 2023-507695-52-00 check the CTIS register for the current data. To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor…

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in
participants with primary progressive multiple sclerosis (PERSEUS)

This study has been transitioned to CTIS with ID 2024-514495-41-00 check the CTIS register for the current data. Primary: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in PPMSSecondary:1. To evaluate…

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-503441-55-00 check the CTIS register for the current data. The primary objective is to compare the efficacy of Tec-Dara (Arm A) with DPd/DVd (Arm B) in participants who have received 1 to 3 prior…

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

This study has been transitioned to CTIS with ID 2023-509750-58-00 check the CTIS register for the current data. In this study, we look at how safe the new medicinal product rusfertide is for the treatment of Polycythemia vera. And how well it works…

A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes

This study has been transitioned to CTIS with ID 2023-506981-30-00 check the CTIS register for the current data. Main objective:The primary objective is to demonstrate that combination therapy using finerenone and empagliflozin is superior in…

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505749-14-00 check the CTIS register for the current data. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab…

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator*s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study has been transitioned to CTIS with ID 2023-504830-23-00 check the CTIS register for the current data. Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)

Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes

This study has been transitioned to CTIS with ID 2023-506923-27-00 check the CTIS register for the current data. Primary objectiveTo confirm superiority of oral semaglutide at the maximum tolerated dose* (3 mg, 7 mg or 14 mg) versus placebo on…

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

This study has been transitioned to CTIS with ID 2023-504360-42-00 check the CTIS register for the current data. The Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients (LEGACY) trial will investigate…

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE

This study has been transitioned to CTIS with ID 2024-513992-42-00 check the CTIS register for the current data. The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through…

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications

This study has been transitioned to CTIS with ID 2024-513861-38-00 check the CTIS register for the current data. Primary Objective• To evaluate the effect of EDP-938 compared with placebo on the progression of RSV infection by assessment of clinical…

The (cost-)effectiveness of an innovative, personalised intervention of therapeutic VirtuAl Reality IntEgrated within physioTherapY for a subgroup of complex chronic low back pain patients

Our primary objective is to investigate whether a personalised, physiotherapy intervention with integrated therapeutic virtual reality (VR) is (cost-)effective at 3 months and 12 months follow-up, compared to usual physiotherapy, in a subgroup of…

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

This study has been transitioned to CTIS with ID 2023-510455-28-00 check the CTIS register for the current data. This study is being carried out to investigate the treatment with benralizumab in patients with active HES.The purpose of this study is…

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-506576-27-00 check the CTIS register for the current data. The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent…

Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1

This study has been transitioned to CTIS with ID 2023-506253-38-00 check the CTIS register for the current data. Primary- To test the hypothesis that lasmiditan high dose is superior to placebo in the acute treatment of a migraine attack in…

Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

This study has been transitioned to CTIS with ID 2024-510800-35-00 check the CTIS register for the current data. Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and…

A Phase III Randomized, Open-Label, Multicenter Study to Determine the
Efficacy and Safety of Durvalumab in Combination With Tremelimumab
and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab
Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or
Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive
Bladder Cancer (VOLGA)

This study has been transitioned to CTIS with ID 2023-507342-84-00 check the CTIS register for the current data. (1) Main objective:Safety Run-In (SRI):To assess the safety and tolerability of durvalumab + tremelimumab + EV in participants with MIBC…

Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting;Substudy: Characterization of Intermediate Lesions

• Demonstrate that PCI guided by iFR Co-registration is associated with superior clinical outcomes compared to PCI guided by angiography alone• To evaluate the cost-effectiveness of physiology guidance with SyncVision compared to a standard of care…

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

This study has been transitioned to CTIS with ID 2023-509908-15-00 check the CTIS register for the current data. All primary and secondary objectives will compare zanubrutinib (also known as BGB-3111) plus rituximab followed by zanubrutinib…

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma (KEYNOTE 966)

This study has been transitioned to CTIS with ID 2023-506657-38-00 check the CTIS register for the current data. To compare pembrolizumab plus gemcitabine plus cisplatin to placebo plus gemcitabine plus cisplatin with respect to overall survival (OS…